Global Artificial Intelligence (AI) in Cancer 麻豆原创 Research Report 2023

Publication ID:

PB502242434

Publication Date:

February 9, 2023

Pages:

100

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Integration of听AI听technology in听cancer听care could improve the accuracy and speed of diagnosis, aid clinical decision-making, and lead to better health outcomes.听AI-guided clinical care has the potential to play an important role in reducing health disparities, particularly in low-resource settings.
Highlights
The global Artificial Intelligence (AI) in Cancer market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Artificial Intelligence (AI) in Cancer is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Artificial Intelligence (AI) in Cancer is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Artificial Intelligence (AI) in Cancer in Diagnosis is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Artificial Intelligence (AI) in Cancer include IBM, Microsoft, NVIDIA, Intel, GE Healthcare, Johnson & Johnson, Cancer Center.ai, Digital Reasoning and Varian Medical Systems, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Artificial Intelligence (AI) in Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Artificial Intelligence (AI) in Cancer.
The Artificial Intelligence (AI) in Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Artificial Intelligence (AI) in Cancer market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Artificial Intelligence (AI) in Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
IBM
Microsoft
NVIDIA
Intel
GE Healthcare
Johnson & Johnson
Cancer Center.ai
Digital Reasoning
Varian Medical Systems
Niramai
Densitas
MammoScreen
MVision AI
Volpara
LungLifeAI
Segment by Type
Surgery
Radiotherapy
Chemotherapy
Immunotherapy
Phototherapy
Gene Therapy
Sonodynamic Therapy
Segment by Application
Diagnosis
Therapy
Prognosis
Health Management
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Artificial Intelligence (AI) in Cancer companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Artificial Intelligence (AI) in Cancer 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Surgery
1.2.3 Radiotherapy
1.2.4 Chemotherapy
1.2.5 Immunotherapy
1.2.6 Phototherapy
1.2.7 Gene Therapy
1.2.8 Sonodynamic Therapy
1.3 麻豆原创 by Application
1.3.1 Global Artificial Intelligence (AI) in Cancer 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Diagnosis
1.3.3 Therapy
1.3.4 Prognosis
1.3.5 Health Management
1.3.6 Research
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Artificial Intelligence (AI) in Cancer 麻豆原创 Perspective (2018-2029)
2.2 Artificial Intelligence (AI) in Cancer Growth Trends by Region
2.2.1 Global Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Artificial Intelligence (AI) in Cancer Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Artificial Intelligence (AI) in Cancer Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Artificial Intelligence (AI) in Cancer 麻豆原创 Dynamics
2.3.1 Artificial Intelligence (AI) in Cancer Industry Trends
2.3.2 Artificial Intelligence (AI) in Cancer 麻豆原创 Drivers
2.3.3 Artificial Intelligence (AI) in Cancer 麻豆原创 Challenges
2.3.4 Artificial Intelligence (AI) in Cancer 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Artificial Intelligence (AI) in Cancer Players by Revenue
3.1.1 Global Top Artificial Intelligence (AI) in Cancer Players by Revenue (2018-2023)
3.1.2 Global Artificial Intelligence (AI) in Cancer Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Artificial Intelligence (AI) in Cancer 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Artificial Intelligence (AI) in Cancer Revenue
3.4 Global Artificial Intelligence (AI) in Cancer 麻豆原创 Concentration Ratio
3.4.1 Global Artificial Intelligence (AI) in Cancer 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Artificial Intelligence (AI) in Cancer Revenue in 2022
3.5 Artificial Intelligence (AI) in Cancer Key Players Head office and Area Served
3.6 Key Players Artificial Intelligence (AI) in Cancer Product Solution and Service
3.7 Date of Enter into Artificial Intelligence (AI) in Cancer 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Artificial Intelligence (AI) in Cancer Breakdown Data by Type
4.1 Global Artificial Intelligence (AI) in Cancer Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Artificial Intelligence (AI) in Cancer Forecasted 麻豆原创 Size by Type (2024-2029)
5 Artificial Intelligence (AI) in Cancer Breakdown Data by Application
5.1 Global Artificial Intelligence (AI) in Cancer Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Artificial Intelligence (AI) in Cancer Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Artificial Intelligence (AI) in Cancer 麻豆原创 Size (2018-2029)
6.2 North America Artificial Intelligence (AI) in Cancer 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2018-2023)
6.4 North America Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Artificial Intelligence (AI) in Cancer 麻豆原创 Size (2018-2029)
7.2 Europe Artificial Intelligence (AI) in Cancer 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2018-2023)
7.4 Europe Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Artificial Intelligence (AI) in Cancer 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Artificial Intelligence (AI) in Cancer 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Artificial Intelligence (AI) in Cancer 麻豆原创 Size (2018-2029)
9.2 Latin America Artificial Intelligence (AI) in Cancer 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Artificial Intelligence (AI) in Cancer 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Artificial Intelligence (AI) in Cancer 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Artificial Intelligence (AI) in Cancer 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 IBM
11.1.1 IBM Company Detail
11.1.2 IBM Business Overview
11.1.3 IBM Artificial Intelligence (AI) in Cancer Introduction
11.1.4 IBM Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.1.5 IBM Recent Development
11.2 Microsoft
11.2.1 Microsoft Company Detail
11.2.2 Microsoft Business Overview
11.2.3 Microsoft Artificial Intelligence (AI) in Cancer Introduction
11.2.4 Microsoft Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.2.5 Microsoft Recent Development
11.3 NVIDIA
11.3.1 NVIDIA Company Detail
11.3.2 NVIDIA Business Overview
11.3.3 NVIDIA Artificial Intelligence (AI) in Cancer Introduction
11.3.4 NVIDIA Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.3.5 NVIDIA Recent Development
11.4 Intel
11.4.1 Intel Company Detail
11.4.2 Intel Business Overview
11.4.3 Intel Artificial Intelligence (AI) in Cancer Introduction
11.4.4 Intel Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.4.5 Intel Recent Development
11.5 GE Healthcare
11.5.1 GE Healthcare Company Detail
11.5.2 GE Healthcare Business Overview
11.5.3 GE Healthcare Artificial Intelligence (AI) in Cancer Introduction
11.5.4 GE Healthcare Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.5.5 GE Healthcare Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Artificial Intelligence (AI) in Cancer Introduction
11.6.4 Johnson & Johnson Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.6.5 Johnson & Johnson Recent Development
11.7 Cancer Center.ai
11.7.1 Cancer Center.ai Company Detail
11.7.2 Cancer Center.ai Business Overview
11.7.3 Cancer Center.ai Artificial Intelligence (AI) in Cancer Introduction
11.7.4 Cancer Center.ai Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.7.5 Cancer Center.ai Recent Development
11.8 Digital Reasoning
11.8.1 Digital Reasoning Company Detail
11.8.2 Digital Reasoning Business Overview
11.8.3 Digital Reasoning Artificial Intelligence (AI) in Cancer Introduction
11.8.4 Digital Reasoning Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.8.5 Digital Reasoning Recent Development
11.9 Varian Medical Systems
11.9.1 Varian Medical Systems Company Detail
11.9.2 Varian Medical Systems Business Overview
11.9.3 Varian Medical Systems Artificial Intelligence (AI) in Cancer Introduction
11.9.4 Varian Medical Systems Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.9.5 Varian Medical Systems Recent Development
11.10 Niramai
11.10.1 Niramai Company Detail
11.10.2 Niramai Business Overview
11.10.3 Niramai Artificial Intelligence (AI) in Cancer Introduction
11.10.4 Niramai Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.10.5 Niramai Recent Development
11.11 Densitas
11.11.1 Densitas Company Detail
11.11.2 Densitas Business Overview
11.11.3 Densitas Artificial Intelligence (AI) in Cancer Introduction
11.11.4 Densitas Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.11.5 Densitas Recent Development
11.12 MammoScreen
11.12.1 MammoScreen Company Detail
11.12.2 MammoScreen Business Overview
11.12.3 MammoScreen Artificial Intelligence (AI) in Cancer Introduction
11.12.4 MammoScreen Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.12.5 MammoScreen Recent Development
11.13 MVision AI
11.13.1 MVision AI Company Detail
11.13.2 MVision AI Business Overview
11.13.3 MVision AI Artificial Intelligence (AI) in Cancer Introduction
11.13.4 MVision AI Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.13.5 MVision AI Recent Development
11.14 Volpara
11.14.1 Volpara Company Detail
11.14.2 Volpara Business Overview
11.14.3 Volpara Artificial Intelligence (AI) in Cancer Introduction
11.14.4 Volpara Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.14.5 Volpara Recent Development
11.15 LungLifeAI
11.15.1 LungLifeAI Company Detail
11.15.2 LungLifeAI Business Overview
11.15.3 LungLifeAI Artificial Intelligence (AI) in Cancer Introduction
11.15.4 LungLifeAI Revenue in Artificial Intelligence (AI) in Cancer Business (2018-2023)
11.15.5 LungLifeAI Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

IBM
Microsoft
NVIDIA
Intel
GE Healthcare
Johnson & Johnson
Cancer Center.ai
Digital Reasoning
Varian Medical Systems
Niramai
Densitas
MammoScreen
MVision AI
Volpara
LungLifeAI

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.